Immunomodulators (IL-6 pathway biologics)
- Block IL-6 receptor/signaling
- Tocilizumab/sarilumab are prototypes
- Uses include RA, GCA + cytokine release syndrome
- Infection, neutropenia + LFT effects matter
- Can raise lipids
- CRP may be suppressed despite serious infection
Class at a glance
- Block IL-6 receptor/signaling
Practical pearls
- Tocilizumab/sarilumab are prototypes
Clinical role
- Uses include RA, GCA + cytokine release syndrome
- Can raise lipids
Other clinical roles
- Infection, neutropenia + LFT effects matter
- CRP may be suppressed despite serious infection
Self-check
- How can IL-6 pathway biologics affect lipids?
They can raise them. - Can CRP remain suppressed despite serious infection during IL-6 blockade?
Yes.
Drugs in this class (3)
All drug classes · Open Immunomodulators (IL-6 pathway biologics) in the interactive console ↗